Login to Your Account

Focus Now on Preclinical Pipeline

Immtech Drops Pafuramidine on Safety Concerns, Stock Tumbles

By Jennifer Boggs

Tuesday, February 26, 2008
Shares of Immtech Pharmaceuticals Inc. plunged for the second time in two months after the company said it was discontinuing development of lead drug pafuramidine due to safety concerns. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription